These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

510 related articles for article (PubMed ID: 9783928)

  • 61. An analysis of the effect of statin use on the efficacy of bacillus calmette-guerin treatment for transitional cell carcinoma of the bladder.
    Berglund RK; Savage CJ; Vora KC; Kurta JM; Cronin AM
    J Urol; 2008 Oct; 180(4):1297-300; discussion 1300. PubMed ID: 18707737
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin.
    Thalmann GN; Sermier A; Rentsch C; Möhrle K; Cecchini MG; Studer UE
    J Urol; 2000 Dec; 164(6):2129-33. PubMed ID: 11061941
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Transient anuria requiring nephrostomy after intravesical bacillus Calmette-Guérin instillations for superficial bladder cancer.
    Kaneko T; Fujita K; Homma Y
    Int J Urol; 2006 Mar; 13(3):294-5. PubMed ID: 16643629
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Adjuvant intravesical instillation for primary T1G3 bladder cancer: BCG versus MMC in Korea.
    Cho IC; Kim EK; Joung JY; Seo HK; Chung J; Park WS; Lee KH
    Anticancer Res; 2012 Apr; 32(4):1493-8. PubMed ID: 22493392
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A randomized prospective study of intravesical prophylaxis in non-musle invasive bladder cancer at intermediate risk of recurrence: mitomycin chemotherapy vs BCG immunotherapy.
    Mangiarotti B; Trinchieri A; Del Nero A; Montanari E
    Arch Ital Urol Androl; 2008 Dec; 80(4):167-71. PubMed ID: 19235434
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Does isoniazid reduce side effects of intravesical bacillus Calmette-Guerin therapy in superficial bladder cancer? Interim results of European Organization for Research and Treatment of Cancer Protocol 30911.
    Vegt PD; van der Meijden AP; Sylvester R; Brausi M; Höltl W; de Balincourt C
    J Urol; 1997 Apr; 157(4):1246-9. PubMed ID: 9120912
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly bacillus Calmette-Guérin (BCG) or alternating BCG and interferon-α2b instillations: prospective randomised FinnBladder-4 study.
    Järvinen R; Marttila T; Kaasinen E; Rintala E; Aaltomaa S; Kallio J; Liukkonen T; Puolakka VM; Seppänen M; Tuhkanen K; Vaarala M; Viitanen J; Boström PJ;
    Eur Urol; 2015 Oct; 68(4):611-7. PubMed ID: 25748117
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial.
    Di Stasi SM; Giannantoni A; Giurioli A; Valenti M; Zampa G; Storti L; Attisani F; De Carolis A; Capelli G; Vespasiani G; Stephen RL
    Lancet Oncol; 2006 Jan; 7(1):43-51. PubMed ID: 16389183
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Evolution and clinical significance of the T cell proliferative and cytokine response directed against the fibronectin binding antigen 85 complex of bacillus Calmette-Guerin during intravesical treatment of superficial bladder cancer.
    Zlotta AR; Drowart A; Van Vooren JP; de Cock M; Pirson M; Palfliet K; Jurion F; Vanonckelen A; Simon J; Schulman CC; Huygen K
    J Urol; 1997 Feb; 157(2):492-8. PubMed ID: 8996341
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A 12 versus 6-week course of bacillus Calmette-Guerin prophylaxis for the treatment of high risk superficial bladder cancer.
    Gruenwald IE; Stein A; Rashcovitsky R; Shifroni G; Lurie A
    J Urol; 1997 Feb; 157(2):487-91. PubMed ID: 8996340
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Alternating mitomycin C and bacillus Calmette-Guerin instillation therapy for carcinoma in situ of the bladder. The Finnbladder Group.
    Rintala E; Jauhiainen K; Rajala P; Ruutu M; Kaasinen E; Alfthan O
    J Urol; 1995 Dec; 154(6):2050-3. PubMed ID: 7500456
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [A prospective and randomized study of the complete response, index of recurrences and progression in superficial bladder carcinoma treated with mitomycin C alone versus mitomycin C and BCG alternatively].
    Gelabert-Mas A; Arango Toro O; Bielsa Gali O; Lladó Carbonell C
    Arch Esp Urol; 1993 Jun; 46(5):379-82. PubMed ID: 8342972
    [TBL] [Abstract][Full Text] [Related]  

  • 73. BCG-RIVM versus BCG-Tice versus mitomycin-C in superficial bladder cancer. Rationale, design, and interim analysis of the trial of the South-East Cooperative Urological Group, The Netherlands.
    Witjes WP; van der Meijden PM; Roos EP; Witjes JA; Steerenberg PA; Doesburg W; Debruyne FM
    Prog Clin Biol Res; 1992; 378():59-67. PubMed ID: 1301587
    [No Abstract]   [Full Text] [Related]  

  • 74. Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer.
    Shelley MD; Court JB; Kynaston H; Wilt TJ; Coles B; Mason M
    Cochrane Database Syst Rev; 2003; (3):CD003231. PubMed ID: 12917955
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Instillation therapy in superficial urinary bladder cancer. Finnbladder Group.
    Jauhiainen KE; Alfthan OS
    Scand J Urol Nephrol Suppl; 1991; 138():179-85. PubMed ID: 1785001
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. Participating Clinics.
    Krege S; Giani G; Meyer R; Otto T; Rübben H
    J Urol; 1996 Sep; 156(3):962-6. PubMed ID: 8709374
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Intravesical Bacillus Calmette-Guerin for treating bladder cancer.
    Boyd LA
    Urol Nurs; 2003 Jun; 23(3):189-91, 199; quiz 192. PubMed ID: 12861735
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity.
    Böhle A; Jocham D; Bock PR
    J Urol; 2003 Jan; 169(1):90-5. PubMed ID: 12478111
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer].
    Yamada Y; Washida H; Tozawa K; Honma H; Kang K
    Hinyokika Kiyo; 1994 Jul; 40(7):575-9. PubMed ID: 8085517
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Alternating mitomycin C and bacillus Calmette-Guerin instillation prophylaxis for recurrent papillary (stages Ta to T1) superficial bladder cancer. Finnbladder Group.
    Rintala E; Jauhiainen K; Kaasinen E; Nurmi M; Alfthan O
    J Urol; 1996 Jul; 156(1):56-9; discussion 59-60. PubMed ID: 8648837
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.